Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

New York, New York 10021


Purpose:

This Phase Ib dose escalation study is designed to characterize the safety, tolerability and preliminary efficacy of i.v. panobinostat (LBH589) in combination with docetaxel and prednisone in the 1st line treatment of patients with hormone refractory prostate cancer.


Criteria:

Inclusion criteria: - HRPC patients - Evidence of disease progression - Self care, able to perform light work activities - Willing to use contraception throughout the study and for 12 weeks after study completion Exclusion criteria: - History of other cancers not curatively treated with no evidence of disease for more than 5 years. - Prior radiotherapy within 3 weeks of starting study treatment - Prior radiopharmaceuticals (strontium, samarium). - Impaired cardiac function - Heart disease - Liver or renal disease with impaired functions. Other protocol-defined inclusion/exclusion criteria may apply


NCT ID:

NCT00663832


Primary Contact:

Study Director
Novartis Pharmaceuticals
Novartis Pharmaceuticals


Backup Contact:

N/A


Location Contact:

New York, New York 10021
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.